长春高新：金赛药业将获得3款产品在中国大陆范围内的独家代理权益

Core Viewpoint - Changchun High-tech (000661) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights for three products in the mainland market [1] Group 1: Partnership Details - The partnership involves Changchun High-tech's subsidiary, Jinsai Pharmaceutical, which will pay an upfront fee of €32.7 million for the collaboration [1] - Jinsai Pharmaceutical will also make a milestone payment of €40 million based on the clinical trial regulatory approval progress for the sublingual tablet (ACARIZAX) for adults, adolescents, and children in China [1] - Future payments of up to €105 million may be made depending on the sales performance of the products in the Chinese market [1]